v3.24.1.u1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Consolidated Statements of Operations and Comprehensive Loss    
Revenue $ 433,026 $ 0
Cost of goods sold 294,056 0
Gross profit 138,970 0
Operating expenses:    
Research and development 764,581 1,273,536
Selling, general and administrative 15,416,388 3,825,512
Total operating expenses 16,180,969 5,099,048
Loss from operations (16,041,999) (5,099,048)
Other income (expense):    
Foreign exchange transaction gain 45,753 0
Change in fair value of share liability (194,540) 150,527
Interest income 9,074 3,382
Interest expense (118,547) 0
Total other (expense) income (258,260) 153,909
Loss before income tax expense (16,300,259) (4,945,139)
Income tax provision 6,133 0
Net loss before allocation to noncontrolling interests (16,294,126) (4,945,139)
Less: Net loss attributable to noncontrolling interests (7,892) 0
Net loss attributable to ASP Isotopes Inc. shareholders $ (16,286,234) $ (4,945,139)
Net loss per share attributable to ASP Isotopes Inc. shareholders, basic and diluted $ (0.49) $ (0.18)
Weighted average shares of common stock outstanding, basic and diluted 33,066,708 26,793,748
Comprehensive loss:    
Net loss before allocation to noncontrolling interests $ (16,294,126) $ (4,945,139)
Foreign currency translation (1,176,012) 236,307
Total comprehensive loss before allocation to noncontrolling interests (17,470,138) (4,708,832)
Less: Comprehensive loss attributable to noncontrolling interests 27,255 0
Comprehensive loss attributable to ASP Isotopes Inc. $ (17,497,393) $ (4,708,832)

Source